Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06577467 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Sep 1, 2026 → Sep 1, 2027
See other at-risk trials from National Institute of Neurological Disorders and Stroke (NINDS)

Record History

The 50 most recent of 151 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Sep 1, 2026 to Sep 1, 2027 Eligibility criteria expanded, about 40 words · Study description expanded, about 5 words Show 2 more changesShow less
    • Eligibility criteria expanded, about 40 words
    • Study description expanded, about 5 words
  2. Minor 8 versions Re-verified since Apr 15, 2026, no change to tracked fieldsv143-v150
  3. Minor Eligibility criteria shortened, about 2 wordsv142 See this version in full on ClinicalTrials.gov ↗
  4. Minor 5 versions Re-verified since Aug 1, 2025, no change to tracked fieldsv137-v141
  5. Minor Study Status, Eligibilityv136
Show 34 earlier versionsHide 34 earlier versions
  1. Minor 3 versions Re-verified since May 21, 2025, no change to tracked fieldsv133-v135
  2. Minor Start date changed from estimate of Apr 3, 2025 to Mar 27, 2025v132
  3. Minor Start date: Apr 1, 2025 to Apr 3, 2025v131
  4. Minor Start date: Mar 31, 2025 to Apr 1, 2025v130
  5. Minor Start date: Mar 30, 2025 to Mar 31, 2025v129
  6. Minor Start date: Mar 27, 2025 to Mar 30, 2025v128
  7. Minor Start date: Mar 26, 2025 to Mar 27, 2025v127
  8. Minor Start date: Mar 25, 2025 to Mar 26, 2025v126
  9. Minor Start date: Mar 24, 2025 to Mar 25, 2025v125
  10. Minor Start date: Mar 23, 2025 to Mar 24, 2025v124
  11. Minor Start date: Mar 20, 2025 to Mar 23, 2025v123
  12. Minor Start date: Mar 19, 2025 to Mar 20, 2025v122
  13. Minor Start date: Mar 18, 2025 to Mar 19, 2025v121
  14. Minor Start date: Mar 17, 2025 to Mar 18, 2025v120
  15. Minor Start date: Mar 16, 2025 to Mar 17, 2025v119
  16. Minor Start date: Mar 13, 2025 to Mar 16, 2025v118
  17. Minor Start date: Mar 12, 2025 to Mar 13, 2025v117
  18. Minor Start date: Mar 11, 2025 to Mar 12, 2025v116
  19. Minor Start date: Mar 10, 2025 to Mar 11, 2025v115
  20. Minor Start date: Mar 9, 2025 to Mar 10, 2025v114
  21. Minor Start date: Mar 6, 2025 to Mar 9, 2025v113
  22. Notable Trial status: Not Yet Recruiting to Recruiting Start date: Mar 5, 2025 to Mar 6, 2025v112 Show 1 more changeShow less
    • Start date: Mar 5, 2025 to Mar 6, 2025
  23. Minor Start date: Mar 4, 2025 to Mar 5, 2025v111
  24. Minor Start date: Mar 3, 2025 to Mar 4, 2025v110
  25. Minor Start date: Mar 2, 2025 to Mar 3, 2025v109
  26. Minor Start date: Feb 27, 2025 to Mar 2, 2025v108
  27. Minor Start date: Feb 26, 2025 to Feb 27, 2025v107
  28. Minor Start date: Feb 25, 2025 to Feb 26, 2025v106
  29. Minor Start date: Feb 24, 2025 to Feb 25, 2025v105
  30. Minor Start date: Feb 23, 2025 to Feb 24, 2025v104
  31. Minor Start date: Feb 20, 2025 to Feb 23, 2025v103
  32. Minor Start date: Feb 19, 2025 to Feb 20, 2025v102
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Background: SARS-CoV-2 is the virus that causes COVID-19. Some people who recover from COVID-19 have symptoms that last long after the active infection ends. This is called "long COVID." Sometimes, long COVID can affect the nerves and cause problems with sleep, thinking, the senses, and movement. Researchers want to find out whether people with long COVID have retained inactive remnants of SARS-CoV-2 in their bodies. Objective: To collect tissue samples to see if people with long COVID have remnants of SARS-CoV-2 in their bodies. Eligibility: People 18 years or older who have recovered from COVID-19, both with and without neurologic symptoms. Design: Participants will have 2 to 6 inpatient or outpatient visits over 4 months. Each visit will last 4 to 5 days. Participants will be screened to make sure it is safe to collect tissue samples from their body. They will have a physical and dental exam. They will have imaging scans and a test of their heart function. They will complete questionnaires about their health. They will give blood, urine, saliva, and stool samples. Their sense of taste and smell will be tested. Tissue samples will be taken from the digestive tract, lungs, colon, skin, muscle, lymph nodes, nasal passages, and mouth. Participants may be numbed or sedated for some of the procedures. Swabs will be used to collect cells from inside the mouth and nose. Participants will undergo lumbar puncture. A thin needle will be inserted into their lower back to draw out a sample of the fluid around their spinal cord. Participants will have follow-up phone calls after each clinic visit.
Trial Details
NCT Number NCT06577467
Lead Sponsor National Institute of Neurological Disorders and Stroke (NINDS)
Conditions PASC Post Acute Sequelae of COVID-19
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov